Printer Friendly

Building on the Shoulders of Giants: Is the use of Early Spontaneous Ventilation in the Setting of Severe Diffuse Acute Respiratory Distress Syndrome Actually Heretical?/Devlerin Omuzlanndaki Bina: Siddetli Yaygin Akut Solunum Sikintisi Sendromunda Erken Spontan Ventilasyon Kullanimi Gercekten Sira Disi mi?


Nanos gigantum humeris insidentes: discovering truth by building on previous discoveries. Bernard of Chartres (1)

The present management (1) of severe acute diffuse respiratory distress syndrome [ARDS; PA[O.sub.2]/Fi[O.sub.2] (P/F)<100 on positive end-expiratory pressure (PEEP) [greater than or equal to]5 cm [H.sub.2]O, bilateral infiltrates without cardiac involvement (2)] lowered mortality remarkably from 52%-45% (2) to 32%-24% (3, 4)). Nevertheless, this approach generates a high incidence of critical care unit (CCU)~acquired diseases. Following others (5-9), we extend the use of use spontaneous breathing in the setting of early severe ARDS, given strict physiological guidelines.

Irrespective of the causal disease, diffuse ARDS is a failure of terminal airways to stay open during end-expiration because of inflammation or lung water (on top of atelectasis i.e. focal ARDS). This generates an oxygenation defect: ARDS is not a failure of the respiratory generator, the nerves innervating the ventilatory muscles or the ventilatory muscles. Hence, ARDS should be opposed to failure of the respiratory generator or of its output (e.g. Guillain-Barre, poliomyelitis, etc.), or to acute failure of ventilatory muscles observed during decompensation of chronic obstructive pulmonary disease (COPD). Thus, in ARDS, resting the exhausted ventilatory muscles for a period of time is not required, as in decompensated COPD. In the healthy supine volunteer, spontaneous breathing perfectly matches the ventilation to the perfusion [lowered inspiratory intrathoracic pressure, increasing venous return; diaphragmatic contraction compressing the hepato-splanchnic circulation, furthering venous return (10); and increased heart rate during inspiration, lowering intrapulmonary shunt (11)]. In the setting of diffuse ARDS, pathophysiology requires only the terminal airways to remain open at end-expiration and reduced work of breathing with inspiratory assistance (i.e. pressure support).

Controlled mechanical ventilation (CMV) with paralysis is required only during the restoration of circulation and pH (12), i.e. only during treatment of the acute cardio-ventilatory distress ('shock state' or 'shock'), to suppress further metabolic acidosis. Therefore, swiftness is of much importance. Indeed, ARDS presents with different phases: a) the acute cardio-ventilatory distress when the patient is admitted to the CCU (13) b) early severe diffuse ARDS proper, i.e. stabilized circulatory~ and metabolically-wise and c) late ARDS, not considered here. The three phases require three different therapeutics. Also, ARDS includes a spectrum of ventilatory distress ranging from mild ARDS [hopefully treated with non-invasive ventilation (NIV) (e.g. helmet NIV)] up to severe ARDS and refractory hypoxemia. Further, the stabilization of the acute cardio-ventilatory distress observed in severe ARDS is obviously longer than the stabilization observed in the setting of mild ARDS. Handling single organ failure of a young patient (e.g. flu generating severe ARDS) requires less time to achieve stabilization of the acute cardio-ventilatory distress than that required in the setting of multiple organ failures in an elderly patient presenting with comorbidities [e.g. flu and peritonitis leading to severe ARDS and septic shock requiring renal replacement therapy coupled to veno-venous C[O.sub.2] removal to achieve ultra-low tidal volume (Vt)]. Hopefully, within 3-24 h, the shock is circulatory- and metabolically-wise stabilized, allowing one to address early severe ARDS proper, i.e. the oxygenation defect, hypoxemia and hypoxic drive. Thus, the hypothesis developed here applies in a differentiated manner according to the severity of the syndrome (9).

Given the achievements of conventional management (3, 4), if early spontaneous ventilation (SV) in the setting of early severe stabilized diffuse ARDS is to further improve the outcome, an exacting approach is required. SV is defined here as invasive mechanical ventilation with unimpeded spontaneous breathing effort+pressure support (PS) or airway pressure release ventilation (APRV)+SV (5); SV is opposed to volume-assist control mode (14). Progress beyond the state-of-the-art (3, 4, 15) requires revisiting its rationale: during the acute cardioventilatory distress observed upon arrival into the CCU, paralysis is used for 24 h (16) or 48 h (3) to synchronize perfectly the patient to the ventilator and reduce breath-stacking, lung inflammation and VO. Thus, the time interval necessary to control shock should be used not only for control of shock itself but also to address separately ('analytical' management), as early as possible, the multiple factors involved in the pathophysiology of ARDS (ARDS complex: ARDS 'conundrum'), including circulation (2) (17-19), position, metabolic demands (fever), ventilatory demands (acidosis and C[O.sub.2]) (3) (20-22), sympathetic activation, inflammation (21), agitation. Hypoxemia is considered below separately.

Pitfalls of current management: The step-by-step pathophysiological approach to the acute cardioventilatory distress (13) relies on sound cardio-ventilatory physiology (13). The current management (3, 4, 13) relies on general anaesthesia, paralysis and positive pressure controlled ventilation.

a) General anaesthesia [light 'total intravenous anaesthesia' (TIVA); 'analgosedation' with opioids, Ramsay<3, -5<RASS<-3): General anaesthesia does not allow one to address, separately, the factors delineated above. Rather general anaesthesia masks all the symptoms of heightened respiratory drive simultaneously, which, therefore, cannot be assessed separately anymore. The intensivist is waiting for a miraculous healing of the ARDS complex, rather than acting speedily and tediously to disentangle the factors delineated above, one after the other.

b) Paralysis: Paralysis did not come out of the blue (6). Rather, the use of paralysis is a biased conclusion of experiments showing that i) controlled mandatory ventilation offsets cardiac output redistribution and mortality in the setting of acute experimental tamponade (23) and ii) intracerebroventricular infusion of sodium salicylate leads to hyperventilation, suppressed by paralysis under barbiturates (24). Both experiments demonstrate the need to suppress hyperventilation, acidosis, and ventilatory fatigue. However, none of these experiments can claim that general anaesthesia with controlled mandatory ventilation and paralysis is the only way to achieve minimized work of breathing. Fever control, improved cardiac output and micro-circulation, minimized hypo/hypercapnia, lowered inflammation and cooperative sedation with reduced hyperventilation, all lead to normalised respiratory drive and minimized work of breathing. General anaesthesia and paralysis should stay in the armamentarium of the intensivist just as one useful 'rescue therapy' for the shortest time-interval. Moreover, paralysis is too often extended well beyond the recommended 24 (16) or 48 (3) h limit, generating CCU-acquired pathology.

c) Circulatory impediment: Switching early from controlled mandatory ventilation to spontaneous breathing will reduce the circulatory burden imposed on an unstable patient. Firstly, active squeezing of the hepato-splanchnic sphere by contracting the diaphragm increases the venous return (10) and lowers vasopressor requirement. Secondly, minimized impediment to the right ventricular ejection and left ventricular diastolic filling improves cardiac function.

Given these pitfalls, what would be an alternative to general anaesthesia and paralysis?

A. Metabolic demands. Lowering the temperature by 1[degrees]C lowers V[O.sub.2] by 8%-10% (25), allowing one to reduce V[O.sub.2] by 30%-40% when temperature drops from 39.5[degrees]C to 35.5[degrees]C. In isolated early severe ARDS, metabolic demands should be addressed as soon as possible by lowering V[O.sub.2] ('fever control', i.e. evoked normothermia) (26, 27) with a muscle relaxant (for a time interval as short as possible), paracetamol, surface cooling and/or alpha-2 agonists. Alpha-2 agonists lower the hypothalamic activation threshold of cold defense effectors (28), suppress shivering (29), lower V[O.sub.2] (30) and lower the temperature to approximately 35.5[degrees]C (4) (29-35).

B. Circulation. As far as ARDS is concerned, the goal of circulatory improvement is to help addressing separately lung dysfunction, i.e. oxygenation, hypoxemia and hypoxic drive, as opposed to the other factors delineated above. Therefore, immediate circulatory optimization, such as volume, vasopressor, a pulmonary vasodilator and inotrope (17, 36), based on accepted criteria (lactate, 'C[O.sub.2] gap' and arteriovenous difference) will normalise a low Pv[O.sub.2] effect (17), improving P/F. Checking for a patent foramen ovale (18) will allow one to inform the use of high vs. low PEEP. Evidently, iterative echocardiography will address venous return, right ventricular systolic function and left ventricular diastolic and systolic function (37). The right ventricle should be assessed at least after switching from CMV to SV and after any increase in PEEP.

C. Chemoreflex and respiratory drive. The physiological normalization of the chemoreflex response should progressively normalise Vt and RR This needs itemization.

1) C[O.sub.2] vs. inflammation: A tight control of PaC[O.sub.2] will minimize its influence on the respiratory generator in the setting of late ARDS with rapid shallow breathing (38) and lowered C[O.sub.2] drive, reducing transpulmonary pressure swings (39). In the setting of early severe ARDS, after control of shock, increased respiratory drive exists despite suppression of the C[O.sub.2] drive by hypocapnia observed under spontaneous ventilation (21); possibly, inflammation acting on the respiratory generator evokes the persisting hyperpnea and tachypnea (21). This view (21) supports using the anti-inflammatory effect of alpha-2 agonists (35, 40, 41) to minimize this inflammatory drive impinging on the respiratory generator.

2) Hyperpnea and hypocapnia in early severe ARDS: A larger Vt is observed in patients requiring, on a clinical basis, endotracheal intubation (20) ('intubation'). No major differences are observed with respect to pH and PaC[O.sub.2] between patients failing the NIV test as opposed to patients who can be managed under NIV (pH, 7.45 and 7.41; PaC[O.sub.2], 32 and 36, respectively) (20). A high respiratory drive is postulated. If unrelated to systemic or local acidosis and C[O.sub.2] (20, 42), this heightened drive may be linked to inflammation (21) or fever, with hypoxemia considered separately below. This heightened drive possibly contributes to intra-lung dyscoor-dination ('pendelluft'), observed when SV is superimposed on assisted pressure control ventilation (43). In addition, SV generates more negative pressure from capillary to pleura (transvascular pressure) and a larger fluid shift to the interstitium, i.e. more oedema (44).

i) Pendelluft was reported in one acidotic (pH=7.28, BE=-8) patient (43) presenting with a large Vt (538 mL). No other group report or clinical trial has documented pendelluft. This large Vt suggests a tight control of acidosis (45); a pH>7.30 is necessary before switching to spontaneous ventilation (46). The take-home message is simple: no strong inspiratory effort under spontaneous ventilation, despite high PEEP [legend of figure 1 of (9)]. In a restrictive lung ('baby lung'), 'protective' ventilation (i.e. driving pressure<15 cm [H.sub.2]O (15), Vt<6 mL k[g.sup.-1] (14)) applies, irrespective of controlled mandatory ventilation or spontaneous breathing.

ii) Lymph formation is favoured throughout the ventilatory cycle during SV, at variance with CMV (47, 48); high transvascular pressure (44) and oedema may be offset by higher lymph formation reabsorbed in the bloodstream.

3) The respiratory alkalosis observed in early severe ARDS (20) is converted, after intubation, to respiratory acidosis as a consequence of low driving pressure/Vt combined with general anaesthesia and paralysis. Thus, VC[O.sub.2] should be reduced, to avoid the effect of major respiratory acidosis and hypercapnia on the right ventricle (49) and the respiratory generator (increased Vt and RR), well before the withdrawal of paralysis and general anaesthesia. This implies lowering V[O.sub.2] (see above) and/or using veno-venous C[O.sub.2] removal.

4) Systemic vs. local acidosis: Improving the circulation will normalise the micro-circulation, metabolic/lactic acidosis and a high acidotic respiratory drive. Such a high acidotic drive is associated with a failed trial of spontaneous breathing in the setting of early severe ARDS, under extracorporeal membrane oxygenation (ECMO) (21). Accordingly, patients presenting with ARDS present low PC[O.sub.2] on blood entering the oxygenator (21). Is this surprising fact a consequence of impaired micro-circulation evoking low C[O.sub.2] return? In addition, in the setting of multiple organ failures and early severe ARDS, renal replacement therapy may help to suppress the acidotic drive on the respiratory generator, when improved cardiac output and micro-circulation and lowered ventilatory and metabolic demands are insufficient to rapidly normalise acidosis.

D. Position. 'Upright' position (reverse Trendelenburg, 60[degrees] head-up, 45[degrees] leg-down) (50-52) improves the mechanics of the diaphragm (greater excursion of the diaphragm and unfolding of the juxta-diaphragmatic alveoli). Indeed, the upright position increases P/F in responding severe ARDS (52).

E. Implementation. The hours following admission to the CCU are busy implementing a shock bundle: a) Therapeutic: normalization of volemia, intubation, ventilation with high FiO, high PEEP, vasopressor and inotrope if appropriate, b) Diagnostic: computed tomography (CT) scan, fibre optic bronchoscopy if indicated, iterative arterial and venous blood gases, echocardiography and passive leg raising. c) Physiological interventions: positioning, V[O.sub.2], systemic and local acidosis, VC[O.sub.2], mild permissive hypercapnia. Although the factors delineated above are addressed in a systematic manner, the hypoxic drive is addressed separately:

1) PEEP: CT findings ('focal' vs. 'diffuse' ARDS) will allow one to select low vs. high PEEP, respectively (53). The objective is not to fully reopen the lung ('open lung strategy') (54, 55), but only to recruit a penumbra area, i.e. poorly ventilated alveoli with a low VA/Q ratio. Pa[O.sub.2] and shunt co-relate with the poorly aerated lung, not with atelectatic lung (56, 57). A meta-analysis (58) suggests using high PEEP in severe diffuse ARDS. After stabilization of the acute cardioventilatory distress under CMV with paralysis, PEEP can be set according to either the NIH table (59) [high PEEP (15-24 cm [H.sub.2]O) rather than high Fi[O.sub.2] ] or oxygenation (trial-PEEP to Sa[O.sub.2] >88%-92% in the setting of CMV or lung mechanics (Plat[less than or equal to]25-32 cm [H.sub.2]O (60) vs. end-inspiratory (61) vs. end-expiratory (62) transpulmonary pressure. Spontaneous breathing requires no large transpulmonary pressure swings (high transpulmonary pressure) documented with an oesophageal catheter to achieve acceptable end-inspiratory transpulmonary pressure (<28 cm [H.sub.2]O in spontanously breathing healthy volunteers (63); <25 cm [H.sub.2]O in ARDS patients under CMV (61, 62)) with end-expiratory pressure added as necessary (62). In the setting of spontaneous breathing, this is delineated in legend of figure 1 of reference (9) and has been termed "inverted settings" (64) i.e. high PEEP-low PS. In addition, before switching to SV, a high intrinsic PEEP (65), observed in the setting of early ARDS, will be taken into account to decrease the expiratory work of breathing.

2) Spontaneous breathing: As soon as some improvement is observed (17) with ventilatory and metabolic demands being met (see above), CMV should be switched immediately to SV. This requires setting up PS exactingly: 100% automatic compressed circuit volume compensation ['automatic tube compensation' (66)], low expiratory (67) and inspiratory triggers and steep pressure ramp slope (68). In our hands, the Smart Care software (69) (Evita4XL/Infinity V500, Drager) performs very well in the setting of early severe stabilized ARDS (70) generating low PS without fatigue (low PS-high PEEP). With PS set as delineated above, PS level will compensate primarily for the circuit, the valves (71) and the tracheal tube (72).

Switching from CMV to SV has circulatory (see above) and ventilatory benefits. First, the lowered intrathoracic pressure will allow one to increase PEEP while keeping Pplat as low as possible (5). In turn, high PEEP allows for faster alveolar recruitment (73), addressing the causal process leading to diffuse alveolar damage (recruitable ARDS: inflammation, lung water and atelectrauma in addition to atelectasis). Second, under high PEEP, the sick lung operates on the steepest (74) part of its expiratory pressure-volume curve [legend of figure 1 in (9) for details]. Under spontaneous ventilation and high PEEP, the benefits of a relatively higher compliance are i) a reduction of the work of breathing and ii) low level of PS generating adequate Vt and minimizing 'ventilatory fatigue' (anxiety, nasal flaring, sternal notch retraction, use of accessory muscles and thoracoabdominal dys-coordination). The implication is that, after withdrawal of a course of neuromuscular blockers as short as possible, iterative clinical observation should document the absence of ventilatory fatigue. In addition to the clinical observation, a physiological study using an oesophageal catheter is needed (see above). Third, under SV, high PEEP improves lung function; lung dys-coordination restricted to the triggering phase of inspiration, recruitment of peri-atelectatic regions (poorly ventilated areas with low VA/Q), VA/Q and shunt, improved maximal oxygenation, inspiratory effort and transpulmonary pressure and lowered sedative requirements (75). Fourth, APRV+SV better preserves the VA/Q ratio when compared to PS (5), by allowing diaphragmatic contraction throughout inspiration. The spontaneous expiratory brake evoked by the diaphragm delays the expiratory closure of alveoli (76). APRV+SV lowers ventilation days and CCU stay, approaching significance with respect to mortality in a small sample (77). Accordingly, APRV+SV is undergoing a large epidemiological trial (BIRDS). Clearly, a systematic approach (57) is needed with respect to modes of spontaneous breathing. Thus, recent data (20, 21, 39) reinforce the necessity to a) use CMV with paralysis for a very short interval to avoid patient-self inflicted lung injury (78) only if this time interval is put to proper use, i.e. addressing the factors delineated above b) to switch to SV as soon as the situation has improved (17).

3) Respiratory rate: To achieve spontaneous ventilation without fatigue, lowering RR is the next critical factor (79). As the acidotic and C[O.sub.2] drives are minimized during control of shock under CMV with paralysis, hypoxemia should be the only variable left stimulating the respiratory generator under spontaneous ventilation. The conventional target (Sa[O.sub.2]>88%-95%) (59, 80), applicable to early stabilised severe ARDS under CMV, is not applicable to early stabilised ARDS under spontaneous ventilation. The data show that, under SV, the hypoxic drive will increase RR (81). Thus, under spontaneous ventilation, simultaneously lowering (59) PEEP and Fi[O.sub.2] appears unwise. By contrast, under SV, the alternative is, first, to lower [O.sub.2] to, e.g. Fi[O.sub.2] from 1 to 0.3-0.4 as rapidly as possible ([O.sub.2] toxicity). Although Fi[O.sub.2] is lowered, high PEEP is unchanged; this will maintain Sa[O.sub.2]>95%-100% and RR as low as possible. Second, under SV with 95%<Sa[O.sub.2]<100%, high PEEP is reduced progressively to 10 cm [H.sub.2]O. Should the etiological treatment improve the disease causing ARDS and the analytical management improve ARDS, P/F will increase from well below 100 to above 150-200, over 12-96 h, with a kinetics similar as observed earlier (62, 82). Then, invasive ventilation will be converted to continuous NIV.

4) Normalised sympathetic activity and agitation: During stabilization of shock, sympathetic activation, inflammation and agitation are to be considered separately as they also generate high metabolic demands. In this respect, alpha-2 agonists (dexmedetomidine and clonidine) help pharmacologically the physiological management described above. Indeed, alpha-2 agonists a) normalize the sympathetic hyperactivity back toward baseline levels and b) simultaneously, evoke 'cooperative' (83) sedation (6) (84, 85). Accordingly, alpha-2 agonists suppress hyperventilation evoked by pain and anxiety (70, 86-88) (7). Therefore, immediately (85, 89) following volume loading (90) and intubation, continuous administration of an alpha-2 agonist (8) (without bolus (9)) (91-93) generates sympathetic de-activation, improves micro-circulation (94, 95), lowers V[O.sub.2] (29, 30) during stabilization of shock, reduces intrapulmonary shunt (96, 97) and pulmonary hypertension (98), allows for spontaneous ventilation (99) without respiratory depression (100) or hyperventilation (86), lowers the PaC[O.sub.2] threshold (32), minimizes emergence delirium (101), lowers inflammation (35, 40, 41) and increases diuresis (102). In addition, at variance with general anaesthesia with paralysis, alpha-2 agonists do not interfere with the elastic recoil of the rib cage ("spring out" force). This will leave the chest wall functional residual capacity and diaphragmatic inspiratory and expiratory (76) functions intact.

To conclude, by capitalizing on previous results (3, 4, 13), the present analytical bundle aims at standing on the shoulders of previous investigators (3, 4, 13). Our goal is just to shorten the duration of controlled mandatory ventilation, paralysis and prone position by dissecting the different factors involved in the pathophysiology of early severe diffuse ARDS, including fever control, cardiac output and microcirculation, upright position, normalized chemoresponse to acidosis and C[O.sub.2], normalized work of breathing with low PS-high PEEP, lowered inflammation and early spontaneous ventilation with alpha-2 agonists. An integrative, analytical management leaves, after handling the factors delineated above, hypoxemia as the only factor left to generate a high respiratory drive and to be treated as such with high PEEP and high Fi[O.sub.2] (with inspiratory assistance). Will this fast-track management lead to early extubation and continuous NIV? Does this fast-track management skip late ARDS (fibrosis, myoneuropathy, emergence delirium and CCU-acquired pathology)? This proposal (70, 87, 103-105) requires evidence-based demonstration with respect to physiology and outcome. If the fast-track fails, the intensivist will revert early to 'rescue' therapy that includes CMV, paralysis (3), proning (4), nitric oxide (NO) and ECMO.

Note added in proof : The C[O.sub.2] drive within the genesis of increased ventilatory demand (Carteaux, 2016; ref 20) in early (Crotti, 2017; ref 21)) and late ARDS (Mauri, 2016; ref 39) was emphasized (21, 39). However, suppressing the C[O.sub.2] input on the respiratory generator makes little difference with respect to ventilatory demand. Crotti, 2017 (ref 21) emphasizes systemic inflammation to explain the increased ventilatory demand observed during the acute cardio-ventilatory distress or the early ARDS. Local inflammation or local acidosis at the level of the respiratory generator or pulmonary receptors also require study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - F.P., C.P., M.G., LQ.; Writing Manuscript - F.P., M.G., L.Q.

Conflict of Interest: L Quintin holds US patent 8 703 697 B2 for the treatment of early severe diffuse acute respiratory distress syndrome. The other authors declare no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

Hakem Degerlendirmesi: Dis bagimsiz.

Yazar Katkilan: Fikir - F.P., C.E, M.G., LQ.; Yaziyi Yazan - RE, M.G., L.Q.

Cikar Catismasi: L Quintin, erken siddetli yaygin akut respiratuvar distres sendromunun tedavisi icin ABD patenti 8 703 697 B2'ye sahiptir. Diger yazarlar cikar catismasi bildirmiyor.

Finansal Destek: Yazarlar bu calisma icin finansal destek almadiklarini beyan etmislerdir.


(1.) Fan R, Del Sorbo L, Goligher RC, Hodgson CL, Munshi L, Walkey AJ, et at. An Official American Thoracic Society/Ruropean Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2017; 195: 1253-63. [CrossRef]

(2.) Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell R, Fan R, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307: 2526-33.

(3.) Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Rngl J Med 2010; 363: 1107-16. [CrossRef]

(4.) Guerin C, Reignier J, Richard JC, Beuret F, Gacouin A, Boulain T, et al. Prone positioning in severe acute respiratory distress syndrome. N Rngl J Med 2013; 368: 2159-68. [CrossRef]

(5.) Putensen C, Mutz NJ, Putensen-Himmer G, Zinserling J. Spontaneous breathing during ventilatory support improves ventilation-perfusion distributions in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 159: 1241-8. [CrossRef]

(6.) Wrigge H, Downs JB, Hedenstierna G, Futensen C. Paralysis during mechanical ventilation in acute respiratory distress syndrome: back to the future? Crit Care Med 2004; 32: 1628-9; author reply 9-30.

(7.) Wrigge H, Reske AW. Patient-ventilator asynchrony: adapt the ventilator, not the patient! Crit Care Med 2013; 41: 2240-1.

(8.) Chiumello D. Spontaneous breathing during mechanical ventilation. Crit Care Med 2005; 33: 1170-1. [CrossRef]

(9.) Guldner A, Pelosi F, Gama de Abreu M. Spontaneous breathing in mild and moderate versus severe acute respiratory distress syndrome. Curr Opin Crit Care 2014; 20: 69-76. [CrossRef]

(10.) Permutt S. Circulatory effects of weaning from mechanical ventilation: the importance of transdiaphragmatic pressure. Anesthesiology 1988; 69: 157-60. [CrossRef]

(11.) Yasuma F, Hayano J. Respiratory sinus arrhythmia: why does the heartbeat synchronize with respiratory rhythm? Chest 2004; 125: 683-90.

(12.) Viires N, Sillye G, Aubier M, Rassidakis A, Roussos C. Regional blood flow distribution in dog during induced hypotension and low cardiac output. Spontaneous breathing versus artificial ventilation. J Clin Invest 1983; 72: 935-47. [CrossRef]

(13.) Gattinoni L, Carlesso R, Brazzi L, Cressoni M, Rosseau S, Kluge S, et al. Friday night ventilation: a safety starting tool kit for mechanically ventilated patients. Minerva Anestesiol 2014; 80: 1046-57.

(14.) Network ARDS. Ventilation with lower tidal volume as compared with traditional tidal volume for acute lung injury and the acute respiratory distress syndrome. N Rngl J Med 2000; 342: 1301-8. [CrossRef]

(15.) Amato MB, Meade MO, Slutsky AS, Brochard L, Costa RL, Schoenfeld DA, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Rngl J Med 2015; 372: 747-55. [CrossRef]

(16.) Yoshida T, Fapazian L. When to promote spontaneous respiratory activity in acute respiratory distress patients? Anesthesiology 2014; 120: 1313-5.

(17.) Page B, Vieillard-Baron A, Beauchet A, Aegerter F, Erin S, Jardin F. Low stretch ventilation strategy in acute respiratory distress syndrome: eight years of clinical experience in a single center. Crit Care Med 2003; 31: 765-9. [CrossRef]

(18.) Mekontso Dessap A, Boissier F, Leon R, Carreira S, Campo FR, Lemaire F, et al. Prevalence and prognosis of shunting across patent foramen ovale during acute respiratory distress syndrome. Crit Care Med 2010; 38: 1786-92. [CrossRef]

(19.) Vieillard-Baron A, Schmitt JM, Augarde R Fellahi JL, Prin S, Page B, et al. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med 2001; 29: 1551-5. [CrossRef]

(20.) Carteaux G, Millan-Guilarte T, De Prost N, Razazi K, Abid S, Thille AW, et al. Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal Volume. Crit Care Med 2016; 44: 282-90. [CrossRef]

(21.) Crotti S, Bottino N, Ruggeri GM, Spinelli E, Tubiolo D, Lissoni A, et al. Spontaneous Breathing during Extracorporeal Membrane Oxygenation in Acute Respiratory Failure. Anesthesiology 2017; 126: 678-87. [CrossRef]

(22.) Nobrega AC, O'Leary D, Silva BM, Marongiu E, Piepoli MF, Crisafulli A. Neural regulation of cardiovascular response to exercise: role of central command and peripheral afferents. Biomed Res Int 2014; 2014: 478965. [CrossRef]

(23.) Aubier M, Trippenbach T, Roussos C. Respiratory muscle fatigue during cardiogenic shock. J Appl Physiol Respir Environ Exerc Physiol 1981; 51: 499-508.

(24.) Mascheroni D, Kolobow T, Fumagalli R Moretti MP, Chen V, Buckhold D. Acute respiratory failure following pharmacologically induced hyperventilation: an experimental animal study. Intensive Care Med 1988; 15: 8-14. [CrossRef]

(25.) Young PJ, Saxena M. Fever management in intensive care patients with infections. Crit Care 2014; 18: 206. [CrossRef]

(26.) Manthous CA, Hall JB, Olson D, Singh M, Chatila W, Pohlman A, et al. Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med 1995; 151: 10-4. [CrossRef]

(27.) Schortgen F, Clabault K, Katsahian S, Devaquet J, Mercat A, Deye N, et al. Fever control using external cooling in septic shock: a randomized controlled trial. Am J Respir Crit Care Med 2012; 185: 1088-95. [CrossRef]

(28.) Myers RD), Beleslin DB, Rezvani AH. Hypothermia: role of alpha 1- and alpha 2-noadrenergic receptors in the hypothalamus of the cat. Pharmacol Biochem Behav 1987; 26: 373-9. [CrossRef]

(29.) Liatsi D, Tsapas B, Pampori S, Tsagourias M, Pneumatikos I, Matamis D. Respiratory, metabolic and hemodynamic effects of clonidine in ventilated patients presenting with withdrawal syndrome. Intensive Care Med 2009; 35: 275-81. [CrossRef]

(30.) Quintin L, Viale JP, Annat G, Hoen JP, Butin E, Cottet-Emard JM, et al. Oxygen uptake after major abdominal surgery: effect of clonidine. Anesthesiology 1991; 74: 236-41. [CrossRef]

(31.) Takahashi H, Nishikawa T, Mizutani T, Handa F. Oral clonidine premedication decreases energy expenditure in human volunteers. Can J Anaesth 1997; 44: 268-72. [CrossRef]

(32.) Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992; 77: 1125-33. [CrossRef]

(33.) Ensinger H, Weichel T, Lindner KH, Grunert A, Ahnefeld FW Effects of norepinephrine, epinephrine, and dopamine infusions on oxygen consumption in volunteers. Crit Care Med 1993; 21: 1502-8. [CrossRef]

(34.) Pichot C, Mathern P, Khettab F, Ghignone M, Geloen A, Quintin L. Increased pressor response to noradrenaline during septic shock following clonidine? Anaesth Intensive Care 2010; 38: 784-5.

(35.) Leroy S, Aladin L, Laplace C, Jalem S, Rosenthal J, Abrial A, et al. Introduction of a centrally anti-hypertensive, clonidine, reduces noradrenaline requirements in septic shock caused by necrotizing enterocolitis Am J Emerg Med 2017; 35: e3-377.

(36.) Prewitt RM, Matthay MA, Ghignone M. Hemodynamic management in the adult respiratory distress syndrome. Clin Chest Med 1983; 4: 251-68.

(37.) Repesse X, Aubry A, Vieillard-Baron A. On the complexity of scoring acute respiratory distress syndrome: do not forget hemodynamics! J Thorac Dis 2016; 8: E758-64.

(38.) Kallet RH, Hemphill JC, 3rd, Dicker RA, Alonso JA, Campbell AR, Mackersie RC, et al. The spontaneous breathing pattern and work of breathing of patients with acute respiratory distress syndrome and acute lung injury. Respir Care 2007; 52: 989-95.

(39.) Mauri T, Grasselli G, Suriano G, Eronia N, Spadaro S, Turrini C, et al. Control of Respiratory Drive and Effort in Extracorporeal Membrane Oxygenation Patients Recovering from Severe Acute Respiratory Distress Syndrome. Anesthesiology 2016; 125: 159-67. [CrossRef]

(40.) von Dossow V, Baehr N, Moshirzadeh M, von Heymann C, Braun JP, Hein OV, et al. Clonidine attenuated early proinflammatory response in T-cell subsets after cardiac surgery. Anesth Analg 2006; 103: 809-14. [CrossRef]

(41.) Xu B, Makris A, Thornton C, Ogle R Horvath JS, Hennessy A. Antihypertensive drugs clonidine, diazoxide, hydralazine and furosemide regulate the production of cytokines by placentas and peripheral blood mononuclear cells in normal pregnancy. J Hypertens 2006; 24: 915-22. [CrossRef]

(42.) Carteaux G, de Prost N, Razazi K, Mekontso Dessap A. The authors reply. Crit Care Med 2016; 44: el 154.

(43.) Yoshida T, Torsani V, Gomes S, De Santis RR, Beraldo MA, Costa EL, et al. Spontaneous effort causes occult pendelluft during mechanical ventilation. Am J Respir Crit Care Med 2013; 188: 1420-7. [CrossRef]

(44.) Yoshida T, Fujino Y, Amato M, Kavanagh BP Fifty Years of Research in ARDS. Spontaneous Breathing during Mechanical Ventilation. Risks, Mechanisms, and Management. Am J Respir Crit Care Med 2017; 195: 985-92. [CrossRef]

(45.) Pichot C, Petitjeans F, Ghignone G, Quintin L. Spontaneous ventilation-high PEEP upon severe ARDS: an erratum to further the analysis. Med Hypotheses 2013; 81: 966-7. [CrossRef]

(46.) Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med 1990; 16: 372-7. [CrossRef]

(47.) Moriondo A, Mukenge S, Negrini D. Transmural pressure in rat initial subpleural lymphatics during spontaneous or mechanical ventilation. Am J Physiol Heart Circ Physiol 2005; 289: H263-9.

(48.) Pelosi P, Rocco PR. Effects of mechanical ventilation on the extracellular matrix. Intensive Care Med 2008; 34: 631-9. [CrossRef]

(49.) Mekontso DA, Charron C, Devaquet J, Aboab J, Jardin F, Brochard L, et al. Impact of acute hypercapnia and augmented positive end-expiratory pressure on right ventricle function in severe acute respiratory distress syndrome. Intensive Care Med 2009; 35: 1850-8. [CrossRef]

(50.) Burns SM, Egloff MB, Ryan B, Carpenter R Burns JE. Effect of body position on spontaneous respiratory rate and tidal volume in patients with obesity, abdominal distension and ascites. Am J Crit Care 1994; 3: 102-6.

(51.) Richard JC, Maggiore SM, Mancebo J, Lemaire F, Jonson B, Brochard L. Effects of vertical positioning on gas exchange and lung volumes in acute respiratory distress syndrome. Intensive Care Med 2006; 32: 1623-6. [CrossRef]

(52.) Dellamonica J, Lerolle N, Sargentini C, Hubert S, Beduneau G, Di Marco F, et al. Effect of different seated positions on lung volume and oxygenation in acute respiratory distress syndrome. Intensive Care Med 2013; 39: 1121-7. [CrossRef]

(53.) Rouby JJ, Puybasset L, Cluzel P, Richecoeur J, Lu Q, Grenier P. Regional distribution of gas and tissue in acute respiratory distress syndrome. II. Physiological correlations and definition of an ARDS Severity Score. CT Scan ARDS Study Group. Intensive Care Med 2000; 26: 1046-56. [CrossRef]

(54.) Kirby RR, Downs JB, Civetta JM, Modell JH, Dannemiller FJ, Klein EF, et al. High level positive end expiratory pressure (PEEP) in acute respiratory insufficiency. Chest 1975; 67: 156-63. [CrossRef]

(55.) Borges JB, Carvalho CR, Amato MB. Lung recruitment in patients with ARDS. N Engl J Med 2006; 355: 319-20. [CrossRef]

(56.) Henzler D, Pelosi P, Dembinski R Ullmann A, Mahnken AH, Rossaint R, et al. Respiratory compliance but not gas exchange correlates with changes in lung aeration after a recruitment maneuver: an experimental study in pigs with saline lavage lung injury. Crit Care 2005; 9: R471-82.

(57.) Henzler D, Pelosi P, Bensberg R Dembinski R Quintel M, Pielen V, et al. Effects of partial ventilatory support modalities on respiratory function in severe hypoxemic lung injury. Crit Care Med 2006; 34: 1738-45. [CrossRef]

(58.) Briel M, Meade M, Mercat A, Brower RG, Talmor D, Walter SD, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 2010; 303: 865-73. [CrossRef]

(59.) Brower RG, Lanken PN, Maclntyre N, Matthay MA, Morris A, Ancukiewicz M, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351: 327-36. [CrossRef]

(60.) Mercat A, Richard JC, Vielle B, JaberS, Osman D, DiehlJL, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008; 299: 646-55. [CrossRef]

(61.) Grasso S, Terragni P, Birocco A, Urbino R, Del Sorbo L, Filippini C, et al. ECMO criteria for influenza A (HlNl)-associated ARDS: role of transpulmonary pressure. Intensive Care Med 2012; 38: 395-403. [CrossRef]

(62.) Talmor D, Sarge T, Malhotra A, O'Donnell CR, Ritz R Lisbon A, et al. Mechanical ventilation guided by esophageal pressure in acute lung injury. N Engl J Med 2008; 359: 2095-104. [CrossRef]

(63.) Colebatch HJ, Greaves IA, Ng CK. Exponential analysis of elastic recoil and aging in healthy males and females. J Appl Physiol Respir Environ Exerc Physiol 1979; 47: 683-91.

(64.) Petitjeans F, Quintin L. Non-invasive Failure in de novo acute hypoxemic respiratory failure: high positive end-expiratory pressure-low PS, i.e. "inverted" settings? Crit Care Med 2016; 44: el 153-4.

(65.) Koutsoukou A, Armaganidis A, Stavrakaki-Kallergi C, Vassilakopoulos T, Lymberis A, Roussos C, et al. Expiratory flow limitation and intrinsic positive end-expiratory pressure at zero positive end-expiratory pressure in patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 1590-6. [CrossRef]

(66.) Wrigge H, Zinserling J, Hering R, Schwalfenberg N, Stuber F, von Spiegel T, et al. Cardiorespiratory effects of automatic tube compensation during airway pressure release ventilation in patients with acute lung injury. Anesthesiology 2001; 95: 382-9. [CrossRef]

(67.) Mauri T, Bellani G, Grasselli G, Confalonieri A, Rona R, Patroniti N, et al. Patient-ventilator interaction in ARDS patients with extremely low compliance undergoing ECMO: a novel approach based on diaphragm electrical activity. Intensive Care Med 2013; 39: 282-91. [CrossRef]

(68.) Bonmarchand G, Chevron V, Menard JF, Girault C, Moritz-Berthelot F, Pasquis P, et al. Effects of pressure ramp slope values on the work of breathing during pressure support ventilation in restrictive patients. Crit Care Med 1999; 27: 715-22. [CrossRef]

(69.) Dojat M, Harf A, Touchard D, Lemaire F, Brochard L. Clinical evaluation of a computer-controlled pressure support mode. Am J Respir Crit Care Med 2000; 161: 1161-6. [CrossRef]

(70.) Galland C, Ferrand FX, Cividjian A, Sergent A, Pichot C, Ghignone M, et al. Swift recovery of severe hypoxemic pneumonia upon morbid obesity. Acta Anaesthesiol Belg 2014; 65: 109-17.

(71.) L'Her E, Deye N, Lellouche F, Taille S, Demoule A, Fraticelli A, et al. Physiologic effects of noninvasive ventilation during acute lung injury. Am J Respir Crit Care Med 2005; 172: 1112-8. [CrossRef]

(72.) Shapiro M, Wilson RK, Casar G, Bloom K, Teague RB. Work of breathing through different sized endotracheal tubes. Crit Care Med 1986; 14: 1028-31. [CrossRef]

(73.) Chiumello D, Coppola S, Froio S, Mietto C, Brazzi L, Carlesso E, et al. Time to reach a new steady state after changes of positive end expiratory pressure. Intensive Care Med 2013; 39: 1377-85. [CrossRef]

(74.) Katz JA, Marks JD. Inspiratory work with and without continuous positive airway pressure in patients with acute respiratory failure. Anesthesiology 1985; 63: 598-607. [CrossRef]

(75.) Yoshida T, Roldan R Beraldo MA, Torsani V, Gomes S, De Santis RR, et al. Spontaneous Effort During Mechanical Ventilation: Maximal Injury With Less Positive End-Expiratory Pressure. Crit Care Med 2016; 44: e678-88.

(76.) Pellegrini M, Hedenstierna G, Roneus A, Segelsjo M, Larsson A, Perchiazzi G. The Diaphragm Acts as a Brake During Expiration to Prevent Lung Collapse. Am J Respir Crit Care Med 2017; 195: 1608-16. [CrossRef]

(77.) Zhou Y, Jin X, Lv Y, Wang P, Yang Y, Liang G, et al. Early application of airway pressure release ventilation may reduce the duration of mechanical ventilation in acute respiratory distress syndrome. Intensive Care Med 2017; 43: 1648-59. [CrossRef]

(78.) Brochard L, Slutsky A, Pesenti A. Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. Am J Respir Crit Care Med 2017; 195: 438-42. [CrossRef]

(79.) Cereda M, Foti G, Marcora B, Gili M, Giacomini M, Sparacino ME, et al. Pressure support ventilation in patients with acute lung injury. Crit Care Med 2000; 28: 1269-75. [CrossRef]

(80.) Aggarwal NR, Brower RG. Targeting normoxemia in acute respiratory distress syndrome may cause worse short-term outcomes because of oxygen toxicity. Annals of the American Thoracic Society 2014; 11: 1449-53. [CrossRef]

(81.) Pesenti A, Rossi N, Calori A, Foti G, Rossi GP. Effects of shortterm oxygenation changes on acute lung injury patients undergoing pressure support ventilation. Chest 1993; 103: 1185-9. [CrossRef]

(82.) Villar J, Perez-Mendez L, Lopez J, Belda J, Blanco J, Saralegui I, et al. An early PEEP/FI02 trial identifies different degrees of lung injury in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2007; 176: 795-804. [CrossRef]

(83.) Davies DS, Wing LMH, Reid JL, Neill E, Tipett P, Dollery CT Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 1977; 21: 593-601. [CrossRef]

(84.) Shehabi Y, Botha JA, Ernest D, Freebairn RC, Reade M, Roberts BL, et al. Clinical application, the use of dexmedetomidine in intensive care sedation. Crit Care Shock 2010; 13: 40-50.

(85.) Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting? J Intensive Care Med 2012; 27: 219-37.

(86.) Saito J, Amanai E, Hirota K. Dexmedetomidine-treated hyperventilation syndrome triggered by the distress related with a urinary catheter after general anesthesia: a case report. JA Clin Rep 2017; 3: 22. [CrossRef]

(87.) Pichot C, Picoche A, Saboya-Steinbach M, Rousseau R, de Guys J, Lahmar M, et al. Combination of clonidine sedation and spontaneous breathing-pressure support upon acute respiratory distress syndrome: a feasability study in four patients. Acta Anaesthesiol Belg 2012; 63: 127-33.

(88.) Galland C, Sergent B, Pichot C, Ghignone M, Quintin L. Acute iterative bronchospasm and "do not re-intubate" orders: sedation by an alpha-2 agonist combined with noninvasive ventilation. Am J Emerg Med 2015; 33: 857.e3-5.

(89.) Cann C, Melia D. Sedation in intensive care: should we reach for dexmedetomidine sooner? Br J Hosp Med (Lond) 2017; 78: 598.

(90.) Quenot JP, Binquet C, Pavon A. Cardiovascular collapse: lack of understanding or failure to anticipate heart-lung interaction? Reanimation (Paris) 2012; 21: 710-4.

(91.) Venn RM, Newman PJ, Grounds RM. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003; 29: 201-7. [CrossRef]

(92.) Sauder P, Andreoletti M, Cambonie G, Capellier G, Feissel M, Gall O, et al. Sedation and analgesia in intensive care. French Critical Care Society. Ann Fr Anesth Reanim 2008; 27: 541-51. [CrossRef]

(93.) Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301: 489-99. [CrossRef]

(94.) Kulka PJ, Tryba M, Reimer T, Weisser H. Clonidine prevents tissue-malperfusion during extracorporal circulation. Anesth Analg 1996;82.

(95.) De Kock M, Laterre PF, Van Obbergh L, Carlier M, Lerut J. The effects of intraoperative intravenous clonidine on fluid requirements, hemodynamic variables, and support during liver transplantation: a prospective, randomized study. Anesth Analg 1998; 86: 468-76. [CrossRef]

(96.) Kernan S, Rehman S, Meyer T, Bourbeau J, Caron N, Tobias JD. Effects of dexmedetomidine on oxygenation during onelung ventilation for thoracic surgery in adults. Journal of Minimal Access Surgery 2011; 7: 227-31. [CrossRef]

(97.) Huang SQ, Zhang J, Zhang XX, Liu L, Yu Y, Kang XH, et al. Can Dexmedetomidine Improve Arterial Oxygenation and Intrapulmonary Shunt during One-lung Ventilation in Adults Undergoing Thoracic Surgery? A Meta-analysis of Randomized, Placebo-controlled Trials. Chin Med J (Engl) 2017; 130: 1707-14. [CrossRef]

(98.) Ghignone M, Calvillo O, Quintin L, Noe C, Caple S. Clonidine: a new pulmonary vasodilator. Crit Care Med 1986; 14: 344. [CrossRef]

(99.) Bailey PL, Sperry RJ, Johnson GK, Eldredge SJ, East KA, East TD, et al. Respiratory effects of clonidine alone and combined with morphine, in humans. Anesthesiology 1991; 74: 43-8. [CrossRef]

(100.)Voituron N, Hilaire G, Quintin L. Dexmedetomidine and clonidine induce long-lasting activation of the respiratory rhythm generator of neonatal mice: possible implication for critical care. Respir Physiol Neurobiol 2012; 180: 132-40. [CrossRef]

(101.) Maldonado JR Wysong A, van der Starre PJ, Block T, Miller C, Reitz BA. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery. Psychosomatics 2009; 50: 206-17. [CrossRef]

(102.)Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 2003; 17: 576-84. [CrossRef]

(103.) Pichot C, Petitjeans F, Ghignone M, Quintin L. Is there a place for pressure support ventilation and high end-expiratory pressure combined to alpha-2 agonists early in severe diffuse acute respiratory distress syndrome? Med Hypotheses 2013; 80: 732-7.

(104.) Petitjeans F, Pichot C, Ghignone M, Quintin L. Early severe acute respiratory distress syndrome: What's going on? Part II: controlled vs. spontaneous ventilation? Anaesthesiol Intensive Ther 2016; 48: 339-51. [CrossRef]

(105.) Pichot C, Petitjeans F, Ghignone G, Quintin L. Commentary: Spontaneous ventilation in the setting of early severe stabilized ARDS: heresy? Austin J Pulm Respir Med 2016; 3: 1046.

Fabrice Petitjeans (1), Cyrille Pichot (2), Marco Ghignone (3), Luc Quintin (2)

(1) Hopital D'Instruction des Armees Desgenettes, Lyon, France

(2) Physiology, U of Lyon, Lyon, France

(3) If Kennedy Hospital North Campus, W Palm Beach, FL, USA

Corresponding Author/Sorumlu Yazar:: Luc Quintin E-mail:

Received/Gelis Tarihi : 03.11.2017

Accepted / Kabul Tarihi: 13.06.2018

DOI: 10.5152/TJAR.2018.01947


(2) 'Low Pv[O.sub.2] effect' (17), patent foramen ovale (18), right ventricular dysfunction (19).

(3) Systemic acidosis; local acidosis that implies a thorough improvement of the micro-circulation and a suppression of the metabo-reflex; high PaCO2; all these factors generate high respiratory drive leading to increased Vt and respiratory rate [RR] (20, 21). The metabo-reflex is the metabolic reflex originating in skeletal muscle, activated when blood flow to contracting muscles is insufficient to warrant both 02 delivery and metabolite washout (22), typically in the setting of local low flow and local acidosis.

(4) The lowest temperature in an healthy human at night. Alpha-2 agonists lower V[O.sub.2] (31, 32), especially in the setting of increased demands (29, 30). Furthermore, noradrenaline administration increases V[O.sub.2] (33), whereas alpha-2 agonists lower noradrenaline requirements in the setting of septic shock (34), (35). The overall effect of evoked-normothermia under alpha-2 agonists and lowered NA requirements needs assessment.

(5) Simplistically, under CMV: driving pressure, 20 cm H20+PEEP, 10 cm H20=Pplat[less than or equal to]30 cm H20; under SV: driving pressure, 10 cm H2O+PEEP, 20 cm H20=Pplat[less than or equal to]30 cm H20. Although the formula is wrong, the rationale stands out.

(6) If needed, neuroleptics may be added to alpha-2 agonists (84), (85) (e.g. -3<RASS<-2 under CMV or -2<RASS<0 under SV).

(7) Following alpha-2 agonist administered to healthy volunteers (reference 32), lowered Vt and lowered sensitivity to C02 may explain the absence of hyperventilation and patient-ventilator dyssynchrony in the setting of early severe ARDS or related settings (70, 87, 88) under low PS-high PEEP-alpha-2 agonists and mild permissive hypercapnia.

(8) With paralysis for the shortest interval to address the acute cardioventilatory distress.

(9) The dose [dexmedetomidine, 1.5 [micro]g k[g.sup.-1] [h.sup.-1] (91) or clonidine, 2 [micro]g k[g.sup.-1].[h.sup.-1] (92)] is tentative. It is unknown whether the alpha-2 agonist should achieve a) adequate sedation to allow for nursing (-3<RASS<0) b) vs. the lowest vasopressor requirement or improved micro-circulation (capillary refill, diuresis, lactate<2mM and C02 gap<5-6 mm Hg)?) The speed of the administration of the alpha-2 agonist is important. Obviously when volume is adequate, administration of dexmedetomidine or clonidine, respectively at 1.5 and 2 [micro]g.k[g.sup.-1].[h.sup.-1].sup.1, from intubation onwards is the simplest alternative with conventional sedation withdrawn or preferably not administered at all. When volemia (septic shock and severe ARDS) or auriculo-ventricular (A-V) conduction is inadequate, volemia and/or A-V conduction should be restored first. Then, the alpha-2 agonist is administered and the speed of administration increased step-wise (0.25 [micro]g k[g.sup.-1] [h.sup.-1] for 3 h, followed by iterative echocardiography and passive leg raising and volume loading if appropriate, followed by 0.5 [micro]g k[g.sup.-1] [h.sup.-1] for 3 h with echocardiography, passive leg raising and volume loading, up to maximal dose). No conventional sedation should be administered (ref 84, 89). Rescue sedation (93) using iterative bolus of midazolam allows for stabilization of the sedation evoked by the alpha-2 agonist during the 2-6 h interval needed to achieve sedation with alpha-2 agonists.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Petitjeans, Fabrice; Pichot, Cyrille; Ghignone, Marco; Quintin, Luc
Publication:Turkish Journal of Anaesthesiology and Reanimation
Article Type:Report
Date:Oct 1, 2018
Previous Article:Allergic Bronchopulmonary Aspergillosis/Allerjik Bronkopulmoner Aspergillosis.
Next Article:Anaesthetic Drug Choices of Senior Anaesthetists: An Observational Analysis of Medication Habits in a Tertiary Hospital/Kidemli Anestezistlerin...

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters